Given that TOX inhibits mTOR signaling pathway activation, we also describe the combined effects of rapamycin and PD1 treatment, indicating that rapamycin can be repurposed to improve the immunotherapeutic outcomes of CRC. Here, MTOR is linked to colorectal carcinoma.